PARIS, September 03, 2024--(BUSINESS WIRE)--Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the "Company" or "CARMAT"), today announced its participation in the following scientific and investor conferences during the 2nd half of 2024:
Scientific Conferences
EUMS-Mayo-Hannover-Heart-Conference-2024 September 11 to 14, 2024 (Hanover, Germany) Pr. Haneya (Trier) will present Aeson® during the "TAH update" session on Friday September 13 at 8:30 am CEST. CARMAT teams will be present on stand n°27. The 2023 edition of the congress brought together almost 500 professionals in the field of advanced heart failure and mechanical circulatory assistance devices. For more information, click here.
SFAR, French Society of Anesthesia and Intensive Care September 18 to 20, 2024 (Paris, France) On September 18, at 12:45 pm, CARMAT organizes a symposium on the theme of "Managing patients with artificial hearts", moderated by Dr. Bouglé (Paris) and Prof. Cholley (Paris), with presentations by Dr. Portran (Lyon), Prof. Gaudard (Montpellier), Dr. Moussa (Lille) and Dr. Goéminne (Lille). CARMAT teams will be present on stand n°36. The 2023 edition attracted over 6,000 participants, including anesthesiologists, intensive care nurses, nursing assistants, interns, psychologists, physiotherapists and clinical research associates. For more information, click here.
The French Days of Heart Failure, Cardiomyopathies, Assistance and Cardiac Transplantation (JFIC-CAT) September 19 to 20, 2024 (Caen, France) As part of this event, CARMAT organizes a workshop-debate on "An artificial heart made in France" on September 20 at 12:30 pm, moderated by Prof. Roubille (Montpellier) and Dr. Pozzi (Lyon), with the participation of Dr. Dupasquier (Montpellier), Prof. Lebreton (Paris) and Prof. Guihaire (Plessis-Robinson). CARMAT teams will be present on stand n°1. For more information, click here.
Convegno cardiologia Milano September 23 to 26, 2024 (Milan, Italy) Dr. Russo (Milan) will present Aeson® during the Symposium "Innovazione tecnologica nel trattamento dell’insuficienza cardiaca" For more information, click here.
EACTS Annual Meeting, European Association for Cardio-Thoracic Surgery October 9 to 12, 2024 (Lisbon, Portugal) CARMAT teams will be present on stand n°216. The 2023 event attracted almost 5,000 participants from over a hundred different countries. For more information, click here.
37th Journées de la Pitié October 16 to 18, 2024 (Paris, France) CARMAT will give a presentation during the VAD update session. For more information, click here.
Investor Conferences
European MidCap Event October 2, 2024 (Paris, France) Investor forum organized by CF&B Communication, a leading European facilitator of financial relations between issuers and investors.
Portzamparc BNP Paribas Biotech & Health seminar October 8 to 9, 2024 (virtual event) Investor forum for companies in the healthcare sector, organized by Portzamparc, BNP Paribas' partner investment bank specializing in the French small and mid-cap segment.
EuroLand Corporate investor seminar November 13, 2024 (Paris, France) A forum for management companies to meet with listed companies.
***
About CARMAT
CARMAT is a French MedTech that designs, manufactures and markets the Aeson® artificial heart. The Company’s ambition is to make Aeson® the first alternative to a heart transplant, and thus provide a therapeutic solution to people suffering from end-stage biventricular heart failure, who are facing a well-known shortfall in available human grafts. The world’s first physiological artificial heart that is highly hemocompatible, pulsatile and self-regulated, Aeson® could save, every year, the lives of thousands of patients waiting for a heart transplant. The device offers patients quality of life and mobility thanks to its ergonomic and portable external power supply system that is continuously connected to the implanted prosthesis. Aeson® is commercially available as a bridge to transplant in the European Union and other countries that recognize CE marking. Aeson® is also currently being assessed within the framework of an Early Feasibility Study (EFS) in the United States. Founded in 2008, CARMAT is based in the Paris region, with its head offices located in Vélizy-Villacoublay and its production site in Bois-d’Arcy. The Company can rely on the talent and expertise of a multidisciplinary team of circa 200 highly specialized people. CARMAT is listed on the Euronext Growth market in Paris (Ticker: ALCAR / ISIN code: FR0010907956).
This press release and the information contained herein do not constitute an offer to sell or subscribe, nor a solicitation of an order to buy or subscribe to CARMAT shares in any country.
This press release may contain forward-looking statements by the Company regarding its objectives and prospects. These forward-looking statements are based on the current estimates and anticipations of the Company's management and are subject to risk factors and uncertainties, including those described in its universal registration document filed with the Autorité des Marchés Financiers (AMF) under number D.24-0374 and available on Carmat's website.
Readers' attention is particularly drawn to the fact that the Company's current financing horizon is limited to the end of September 2024, the Company being subject to other risks and uncertainties, such as the Company's ability to implement its strategy, the pace of development of CARMAT's production and sales, the pace and results of ongoing or planned clinical trials, technological evolution and competitive environment, regulatory changes, industrial risks, and all risks associated with the company's growth management. The Company's forward looking statements mentioned in this press release may not be achieved due to these elements or other risk factors and uncertainties, unknown or not considered material and important by the Company to date.
Aeson® is an active implantable medical device commercially available in the European Union and other countries recognizing CE marking. The Aeson® total artificial heart is intended to replace the ventricles of the native heart and is indicated as a bridge to transplant for patients suffering from end-stage biventricular heart failure (INTERMACS classes 1-4) who cannot benefit from maximal medical therapy or a left ventricular assist device (LVAD) and who are likely to undergo a heart transplant within 180 days of implantation. The decision to implant and the surgical procedure must be carried out by healthcare professionals trained by the manufacturer. The documentation (clinician manual, patient manual, and alarm booklet) should be carefully read to understand the features of Aeson® and the information necessary for patient selection and proper use (contraindications, precautions, side effects). In the United States, Aeson® is currently exclusively available as part of an Early Feasibility Study approved by the Food & Drug Administration (FDA).
